Hostname: page-component-586b7cd67f-t8hqh Total loading time: 0 Render date: 2024-11-29T23:16:12.507Z Has data issue: false hasContentIssue false
  • English
  • Français

Current use of atypical antipsychotics

Published online by Cambridge University Press:  16 April 2020

F. Müller-Spahn
Get access

Summary

In terms of the phenomenology of schizophrenia, there are four targets for drug treatments: positive symptoms, negative symptoms, affective dysfunction, and cognitive dysfunction. Because of the side-effects of both conventional antipsychotics and the new atypicals, there still is a need to search for better-tolerated antipsychotics. Conventional antipsychotics have two principal limitations: 30–40% of patients have an insufficient response to them, and they have a large variety of adverse effects. Side-effects will reduce patients’ compliance with treatment, as well as their immediate quality of life, and may therefore unfavorably affect rehabilitation. Four principal features differentiate atypical from conventional antipsychotics, yet have not been established for all atypicals: fewer extrapyramidal side-effects, greater efficacy in the treatment of negative symptoms, specific pharmacological receptor binding profiles, and greater selective effect on the mesolimbic dopamine neurons than on nigrostriatal neurons. The pharmacological profile of amisulpride is completely different to that of other atypical antipsychotics. It has a high selectivity for D2 and D3 dopamine receptors, and thus would be expected to be devoid of unwanted side-effects associated with action on other neurotransmitter systems. It acts preferentially on the mesocortical and mesolimbic systems. It has an earlier onset of action than haloperidol. Amisulpride is a compound with a dual mode of action. At low doses it blocks presynaptic dopamine autoreceptors, inducing an increased dopaminergic neurotransmission, and at high doses it blocks postsynaptic dopaminergic activity. It is at least as effective as haloperidol, flupenthixol, and risperidone in controlling positive symptoms, as well as having efficacy for negative symptoms. It has less propensity to induce weight gain than do other atypical antipsychotics. For the 60–80% of patients with schizophrenia who require long-term treatment, drug tolerability is crucially important, as it will improve compliance, and therefore reduce relapse rate.

Keywords

SchizophreniaAtypical antipsychotic drugsAmisulpridePositive symptomsNegative symptoms
Type
Research Article
Information
European Psychiatry , Volume 17 , Issue S4: Mind Matters - International Schizophrenia Forum , August 2002 , pp. 377s - 384s
Copyright
Copyright Éditions scientifiques et médicales Elsevier SAS 2002

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

Allison, DBMentore, JLHeo, MChandler, LPCappelleri, JCInfante, MC et al. Antipsychotic–induced weight gain: a comprehensive research synthesis. Am J Psychiatry 1999;156:1586–696.Google ScholarPubMed
Boyer, PLecrubier, YPuech, AJDewailly, JAubin, F.Treatment of negative symptoms in schizophrenia with amisulpride. Br J Psychiatry 1995;166:68–72.CrossRefGoogle ScholarPubMed
Colonna, LSaleem, PDondey-Nouvel, LRein W and the Amisulpride study group. Long-term safety and efficacy of amisulpride in subchronic or chronic schizophrenia. International Clinical Psychopharmacology 2000;15:13–22.CrossRefGoogle ScholarPubMed
Danion, JMRein, WFleurot O and the Amisulpride study group. Improvement of schizophrenic patients with primary negative symptoms treated with amisulpride. Am J Psychiatry 1999;156:610–6.Google Scholar
Kapur, S.What really is “atypical” about atypical antipsychotics: Lessons from PET imaging studies. APA 2001, New Orleans, Abstract.Google Scholar
Lecrubier, YBenkert, OKasper, SPeusken, JSechter, D.Amisulpride versus risperidone in schizophrenia: comparing clinical and functional outcome in a 6 month study. ACNP 2000, annual meeting.Google Scholar
Loo, HPoirier-Littre, MTheron, MRein, WFleurot, O.Amisulpride versus placebo in the medium-term treatment of the negative symptoms of schizophrenia. Br J Psychiatry 1997;170:18–22.CrossRefGoogle ScholarPubMed
Möller, HJBoyer, PFleurot, ORein W and PROD–ASLP study group. Improvement of acute exacerbations of schizophrenia with amisulpride: a comparison with haloperidol. Psychopharmacology 1997;132:396–401.Google Scholar
Nyberg, SEriksson, BOxenstierna, GHalldin, CFarde, L.Suggested minimal effective dose of risperidone based on PETmeasured D-2 and 5-HT(2A) receptor occupancy in schizophrenic patients. Am J Psychiatry 1999;156:869–75.CrossRefGoogle Scholar
Nyberg, SNilsson, UOkubo, YHalldin, CFarde, L.Implications of brain imaging for the management of schizophrenia. Int Clin Psychopharmacol 1998;13:15–20.CrossRefGoogle ScholarPubMed
Paillère-Martinot, MLLecrubier, YMartinot, JAubin, F.Improvement of some schizophrenic deficit syndromes with low doses of amisulpride. Am J Psychiatry 1995;152:130–3.Google Scholar
Peuskens, JBech, PMöller, HJBale, RFleurot, OReinWand the Amisulpride study group. Amisulpride vs. Risperidone in the treatment of acute exacerbations of schizophrenia. Psychiatry Research 1999;88:107–17.CrossRefGoogle Scholar
Puech, AFleurot, OReinWand the Amisulpride study group. Amisulpride, an atypical antipsychotic, in the treatment of acute episodes of schizophrenia: a dose-ranging study vs. Haloperidol. Acta Psychiatr Scand 1998;98:65–72.CrossRefGoogle Scholar
Rein, W.Amisulpride improves affective symptoms in acute schizophrenia. Eur Neuropsychopharmacol 1998;8:S231.CrossRefGoogle Scholar
Richelson, E.Preclinical pharmacology of neuroleptics: focus on new generation compounds. J Clin Psychiatry 1996;57:4–11.Google ScholarPubMed
Scatton, BClaustre, YCudennec, AOblin, APerrault, GSanger, DT et al. Amisulpride: from animal pharmacology to therapeutic action. Int Clin Psychopharmacol 1997;12:29–36.CrossRefGoogle ScholarPubMed
Schoemaker, HClaustre, YFage, DRouquier, LChergui, KCuret, O et al. Neurochemical characteristics of amisulpride, an atypical dopamine D2/D3 receptor antagonist with both presynaptic and limbic selectivity. J Pharmacol Exp Ther 1997;280:83–97.Google ScholarPubMed
Seeger, TFSeymour, PASchmidt, AWZorn, SHSchulz, DWLebel, LA et al. Ziprasidone (CP88,059): a new antipsychotic with combined dopamine and serotonin receptor antagonist activity. J Pharmacol Exp Ther 1995;275:101–13.Google Scholar
Taylor, DMMcAskill, R.Atypical antipsychotics and weight gain–a systematic review. Acta Psychiatr Scand 2000;101:416–32.CrossRefGoogle ScholarPubMed
Turjanski, SRein, WThéron, M.Onset of action in acute schizophrenia, amisulpride vs haloperidol. Eur Neuropsychopharmacol 1998;8:S220.CrossRefGoogle Scholar
Wetzel, HGründer, GHillert, APhilipp, MGattaz, WSauer, H et al. (Amisulpride Group). Amisulpride versus flupenthixol in schizophrenia with predominantly positive symptomatology — a double-blind controlled study comparing a selective D2-like antagonist to amixed D1/D2-like antagonist. Psychopharmacology 1998;137:223–32.CrossRefGoogle Scholar
Submit a response

Comments

No Comments have been published for this article.